Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Journal article
Li G. et al, (2022), Lancet, 399, 2212 - 2225
Durability of ChAdOx1 nCov-19 vaccination in people living with HIV.
Journal article
Ogbe A. et al, (2022), JCI Insight
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Journal article
Clemens SAC. et al, (2021), Nature Communications, 12
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.
Journal article
Shakya M. et al, (2021), Lancet Glob Health, 9, e1561 - e1568
Corrigendum to: Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial.
Journal article
Theiss-Nyland K. et al, (2021), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73, 1950 - 1950
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Journal article
Clemens SAC. et al, (2021), Nat Commun, 12
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.
Journal article
Swanson PA. et al, (2021), Science translational medicine, eabj7211 - eabj7211
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Journal article
Feng S. et al, (2021), Nat Med
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Journal article
Liu X. et al, (2021), Lancet, 398, 856 - 869
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
EWER K. et al, (2021), The Lancet
Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
Journal article
Qadri F. et al, (2021), Lancet, 398, 675 - 684
T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.
Journal article
Swanson PA. et al, (2021), medRxiv
Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine
Journal article
Liu X. et al, (2021), SSRN Electronic Journal
Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)
Journal article
Flaxman A. et al, (2021), SSRN Electronic Journal
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial
Journal article
EWER K. et al, (2021), Lancet HIV
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Journal article
Shaw RH. et al, (2021), Lancet, 397, 2043 - 2046
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal article
Barrett JR. et al, (2021), Nature medicine